We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Electrosurgical Platform Combines RF Ablation and Electrocautery

By HospiMedica International staff writers
Posted on 06 Sep 2017
A novel endoscopic submucosal dissection (ESD) device enables minimally invasive removal of early stage cancerous and pre-cancerous lesions in the bowel.

The Creo Medical (Chepstow, United Kingdom) Speedboat RS2 combines bipolar radiofrequency (RF) for demarcated localized cutting and controlled lateral and forward dissection, with precise hemostasis via microwave coagulation. Other features include an integrated injection needle that maintains submucosal lift, obviating the need for instrument changes; a protective hull that reduces the risk of muscle damage; and an optimized shaft design that enables the controlled rotation. Power to the Speedboat RS2 is supplied by the company’s proprietary CROMA RF and microwave generator.

Image: The Speedboat RS2 combined RF/microwave dissection device (Photo courtesy of Creo Medical).
Image: The Speedboat RS2 combined RF/microwave dissection device (Photo courtesy of Creo Medical).

For cutting the mucosa and submucosa, CROMA generates bipolar RF at 400 KHz; to provide hemostasis with microwave coagulation, Croma generates an additional 5.8 GHz of power. In a recent clinical trial that involved 31 patients with complex colorectal polyps, the resected sites healed within three to six months in 97% of the patients; the device also coagulated 50 of the 51 bleeds without causing adverse events. The company intends to further develop the CROMA system for bronchoscopy and laparoscopy procedures.

“Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen and detect early stage and pre-cancerous lesions in the GI tract,” said Craig Gulliford, CEO of Creo. “We believe that with the CROMA system, Speedboat, and our suite of products, we are well positioned to become a leader in this billion-dollar plus market.”

ESD is a technique for therapeutic endoscopy of superficial gastrointestinal neoplasms. Three steps characterize it: injecting fluid into the submucosa to elevate the lesion, cutting the mucosa surrounding the lesion, and dissecting the submucosa beneath the lesion. The ESD technique has rapidly permeated in Japan for treatment of early gastric cancer, due to its excellent results of en-bloc resection, compared to endoscopic mucosal resection (EMR). But ESD requires highly skilled endoscopic surgeons, and a suitable training program is demanded.

Related Links:
Creo Medical


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ventilator
TRventi-3D

Latest Surgical Techniques News

World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets

Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography

AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time